Pfizer agrees to buy Global Blood Therapeutics in deal valued at $5.4 billion: WSJ

Pfizer Inc. /zigman2/quotes/202877789/composite PFE -0.49% has reached an agreement to buy Global Blood Therapeutics Inc. [s :gbt] in a deal valued at $5.4 billion, the Wall Street Journal reported, citing people familiar with the matter. The news comes after the Journal reported Friday that the two were in advanced talks. Pfizer will pay $68.50- a share in cash for Global Blood Therapeutics, which has one of few approved treatments for sickle-cell disease. The companies are expected to announce the deal later Monday. Global Blood Therapeutics shares rose 1.8% in premarket trade Monday, and are up 118% in the year to date, while the S&P 500 /zigman2/quotes/210599714/realtime SPX -0.23% has fallen 13%.

/zigman2/quotes/202877789/composite

Add to watchlist PFE

Pfizer Inc.

US : U.S.: NYSE

$ 32.69

-0.16 -0.49%

Volume: 28.57M

Sept. 22, 2023 4:01p

P/E Ratio

8.71

Dividend Yield

5.02%

Market Cap

$184.57 billion

Rev. per Employee

$939,084

/zigman2/quotes/210599714/realtime

Add to watchlist SPX

S&P 500 Index

US : S&P US

4,320.06

-9.94 -0.23%

Volume: 0.00

Sept. 22, 2023 5:35p